UK Markets open in 6 hrs 50 mins

Hyloris Pharmaceuticals SA (HYL.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
15.05-0.30 (-1.95%)
At close: 5:35PM CET
Sign in to post a message.
  • 4
    4X
    Same pattern every time: good news > the stock moves. News: "Hyloris Expands Cardiovascular Pipeline" (October 8th 2021). Stock: +3,45%.
  • 4
    4X
    Et voilà. Maxigesic IV gets approvals in the UK and Ireland and boom: + 7%.
  • 4
    4X
    Berenberg raises target price from 15 euro to 18 euro (May 18th 2021).
  • 4
    4X
    Double digits again since the approval of Maxigesic® IV (second product to reach the market) in eight European countries (7 september 2020).
  • p
    piet
    Oeps...- 4.20%... ???? News ?
  • p
    piet
    (ABM FN) Hyloris has successfully renegotiated previous licensing agreements with Alter Pharma Group for the pharmaceutical's key products. Hyloris announced this on Thursday morning.

    Hyloris will pay Alter Pharma an amount of 5.25 million euros plus a possible earn-out of 0.5 million euros. In return, future financial obligations to Alter will lapse.

    The renewed license agreements cover Maxigesic IV, HY-075, HY-038 and Fusidic Acid Cream in Canada. Hyloris still bears all development costs for HY-075 and HY-038, but the pharmaceutical company no longer has to share future profits from these products with Alter. For Fusidic Acid Cream, Hyloris gets a bigger share of the profits.

    CEO Stijn Van Rompay spoke of a "big milestone" for Hyloris !
    Good news....
  • 4
    4X
    "Berenberg recommends buying the Hyloris share with a target of 15 euros. In a “blue sky” scenario, the broker is even targeting 36 euros, or a potential of 270%!" (Source: www.en24news.com, 7th January 2021)
  • 4
    4X
    Small uptick on Feb. 5 2021 following the news that 'Hyloris and Purna Female Healthcare announce partnership to develop novel women’s health product'.
  • 4
    4X
    Source: Reuters (24th of June 2021):

    * HYLORIS SUCCESSFULLY RENEGOTIATES LICENSE AGREEMENTS
    FOR LEAD PRODUCTS WITH THE ALTER PHARMA GROUP
    * GAINS HIGHER NET PROFIT MARGIN FOR FUSIDIC ACID CREAM IN
    CANADA
    * ASSUMES SOLE RESPONSIBILITY FOR HY-075 AND HY-038 - FUTURE
    PROFIT SPLIT LAPSES
    * ACQUIRES ALL ROYALTY RIGHTS TO MAXIGESIC IV
    * HAS SUCCESSFULLY RENEGOTIATED AND UNWOUND ITS EARLIER
    LICENSE AGREEMENTS WITH ALTER PHARMA GROUP
    * HYLORIS WILL PAY ALTER PHARMA GROUP A TOTAL LUMP SUM OF
    EUR 5.25 MILLION PLUS EUR 0.5 MILLION POTENTIAL EARN-OUT, THEREBY WAIVING ANY FURTHER FUTURE FINANCIAL OBLIGATIONS TOWARDS ALTER PHARMA GROUP